# ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

> **NCT03394027** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 30 (actual)

## Conditions studied

- Triple Negative Breast Cancer
- Endometrial Cancer
- Hormone Receptor Positive, HER2 Negative Breast Cancer

## Interventions

- **DRUG:** ONC201

## Key facts

- **NCT ID:** NCT03394027
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-17
- **Primary completion:** 2021-03-18
- **Final completion:** 2021-10-07
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03394027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03394027, "ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03394027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*